See the full story in the original article.
Read the original on californiatelegraph.com ↗
Related news
- Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion
CEO Greg Siokas said preliminary nine-month revenue reached about $54.3 million, up 19% year over year, and the company reaffirmed that full-year 2026 revenue will surpass $90 million. The letter notes 2025 revenue of a record $65.3 million, with gross profit up 83% to $7.9 million and gross margin at 12.1%. Reaching the outlook implies fourth-quarter 2026 revenue of about $35.7 million or more, roughly 81% above the approximately $19.7 million of the fourth quarter of 2025. Its newly launched U.S. direct-to-consumer e-commerce business had 8,940 subscriptions and is expected to generate about $15 million in fourth-quarter revenue. The company's proprietary brands are sold in more than 40 countries.
- Cosmos Health Inc .: Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue , U . S . Subscription Growth and Global Expansion
Cosmos Health CEO Greg Siokas wrote to shareholders that preliminary nine-month 2026 revenue was about $54.3 million, up 19%, and the company reaffirmed full-year revenue above $90 million, up about 38%. Fourth-quarter revenue is expected to be about $35.7 million or more, up roughly 81% from the same quarter of 2025, driven by pharmaceutical contract manufacturing and distribution, proprietary brands and U.S. e-commerce. U.S. e-commerce had 8,940 active subscriptions as of October 19, 2026, up 42% in five days, and is expected to generate about $15 million in fourth-quarter revenue. The company also repurchased more than 5.1 million shares for about $1.1 million and set 2029 targets of $200.6 million in revenue and $44.2 million in adjusted EBITDA, with the goal of becoming self-funding by 2027.
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx reported third-quarter 2026 global product net sales of VYVGART of $1.7 billion, up 54% year over year and 13% quarter over quarter. Positive Phase 3 ALKIVIA results showed consistent treatment effects in IMNM and dermatomyositis, with an sBLA for IMNM on track for submission by year-end 2026. The company submitted an sBLA for ocular myasthenia gravis to the FDA, and a pediatric gMG sBLA was accepted for priority review with a PDUFA target date in February 2027. Phase 3 EMPASSION topline results for empasiprubart in MMN are expected in December 2026, while FB102 is advancing to Phase 3 in celiac disease. argenx continues to target treating 50,000 patients, securing 10 labeled indications and advancing five candidates into registrational development by 2030.
- IAMGOLD Provides Update on Côté Gold Mine Operations Ahead of Mine Tour
- IAMGOLD Corporation : IAMGOLD Provides Update on Côté Gold Mine Operations Ahead of Mine Tour
IAMGOLD released preliminary operating results for its Côté Gold Mine for the third quarter of 2026 ahead of an analyst and investor tour on October 22, 2026. Côté produced 64,400 attributable ounces in the quarter (92,000 ounces on a 100% basis), bringing year-to-date attributable output to 184,000 ounces, and mining reached a quarterly record of 12.4 million tonnes. Mill throughput averaged a record 37,100 tonnes per day in September, above the 36,000 tpd nameplate capacity, following an extended annual shutdown in August and the move to owner-only crushing. The company expects higher fourth-quarter output and 2026 attributable production at the lower end of its 270,000 to 310,000 ounce guidance range. An updated mine plan and Mineral Reserve estimate are expected in the fourth quarter of 2026, with the plan expected to support sustained processing of about 40,000 tpd, and full third-quarter results will be reported on November 5, 2026.
- Almadex Expands Claim Block at New Hope, Provides Exploration Update
Almadex Minerals expanded its claim block at the New Hope copper-gold porphyry project in Arizona, covering a broad area of high chargeability east of its two-hole drilling campaign. Mapping and geophysics suggest the drilled holes sit on the western edge of a 2.5 km x 0.75 km zone of phyllic and remnant lithocap alteration, and IP work extended the anomaly 1.95 km east. The second hole returned 6.00 metres at 0.15% copper and 156 ppm molybdenum, including 2.00 metres at 0.34% copper. The company is designing a potential phase II drilling program. At the King target in Colorado, one hole reached 980 metres, and samples are awaiting assay.
Related markets
Latest news
- Why Isn't IBM's Stock Bouncing Back After Strong Earnings Results?
IBM shares fell about 25% in July, their worst day in 115 years, after the company said customers had shifted spending to memory and storage products and delayed major contracts. The third-quarter report on October 21 showed revenue up 5% to $17.1 billion, operating earnings per share up 11% to $2.95, and software growth of 9% at constant currency. The author estimates organic software growth was closer to 4% after excluding the roughly $11 billion Confluent acquisition, and that meeting the roughly $32 billion full-year software target implies fourth-quarter software growth of about 4%. Debt rose to $63.8 billion after $11.4 billion of acquisitions this year, though the dividend appears well covered by free cash flow. The author still sees IBM as a long-term holding for its enterprise AI position and customer base, despite the market's muted reaction.
- IBM Is America’s Worst Big Tech Company
The article argues that IBM, which CEO Arvind Krishna credits with disciplined execution and transformative AI, has missed most major tech shifts over the past fifty years. Quarterly revenue rose 5% to $17.1 billion and net income reached $2.2 billion, up from $1.7 billion a year earlier. The author compares these figures with Nvidia's $60 billion net income last quarter and Microsoft's $90 billion revenue in its most recent quarter. IBM's market cap is $237 billion versus Microsoft's $4 trillion, and the company, the fourth-largest in America in 1993, ranked 66th on the Fortune 500 last year.
- Tesla's Profit Drops 43% as Musk Starts Building Robots and Plans to Sell Driverless Cabs
Tesla's third-quarter net income fell 43% to $787 million from a year earlier, as revenue held flat at $28.05 billion, operating profit dropped 56% to $718 million, and deliveries fell about 2%. Research spending rose 69% to $2.76 billion and capital expenditures more than doubled to $4.73 billion, aimed at humanoid robots and driverless taxis. Tesla has begun producing Optimus robots in Fremont, California, where Musk targets 20,000 a week but says that will take at least a year, with outside deliveries around the end of 2027. Tesla aims to get Cybercabs to customers by the end of 2026, though every one built so far goes to its own robotaxi fleet, no buyer or price has been named, and a federal safety audit is open. Musk also said the Tesla and SpaceX boards have formed committees to study a possible combination, but no terms have been agreed.
- Tesla's Profit Drops 43% as Musk Starts Building Robots and Plans to Sell Driverless Cabs
Tesla's third-quarter net income fell 43% to $787 million from a year earlier, as revenue held flat at $28.05 billion, operating profit dropped 56% to $718 million, and deliveries fell about 2%. Research spending rose 69% to $2.76 billion and capital expenditures more than doubled to $4.73 billion, aimed at humanoid robots and driverless taxis. Tesla has begun producing Optimus robots in Fremont, California, where Musk targets 20,000 a week but says that will take at least a year, with outside deliveries around the end of 2027. Tesla aims to get Cybercabs to customers by the end of 2026, though every one built so far goes to its own robotaxi fleet, no buyer or price has been named, and a federal safety audit is open. Musk also said the Tesla and SpaceX boards have formed committees to study a possible combination, but no terms have been agreed.
- Why Micron Stock Is Falling Hard Today
Shares of Micron Technology (MU) fell about 5.2% by 1:33 p.m. ET as investors worried AI spending could slow. Concerns grew after Nvidia's CEO said capital is scarce for further growth in the AI cloud market, and Meta's shares slid despite beating estimates because it plans $135 billion to $145 billion in capital expenditures this year. Since Micron supplies memory and storage for AI data centers, fears of overspending weighed on its stock. Economic pressure added to the sell-off: the Federal Reserve recently raised rates and hinted at more, oil prices rose on the U.S. war with Iran, and inflation was reported rising faster than expected.
- Taiwan Semiconductor and ASML Are Incredible, but 1 of These Monopoly Chip Stocks Is Far Safer.
The article argues that Taiwan Semiconductor (TSM) and ASML are both near-monopolies, but Taiwan Semiconductor is the safer investment. ASML is the only maker of extreme ultraviolet (EUV) lithography machines, while Taiwan Semiconductor accounted for about 72.5% of chip fabrication revenue in Q2, a scale no rival matches. The author warns that ASML's business depends on chipmakers expanding capacity for the AI build-out, which may slow once that wave ends. ASML also trades at a sizable premium to Taiwan Semiconductor on both 2026 and 2027 earnings estimates.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.